Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables Refunds: 2013-2025

Historic Receivables Refunds for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $2.1 million.

  • Amphastar Pharmaceuticals' Receivables Refunds fell 61.39% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 61.39%. This contributed to the annual value of $1.7 million for FY2024, which is 232.13% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Receivables Refunds of $2.1 million as of Q3 2025, which was up 28.82% from $1.6 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Receivables Refunds high stood at $11.4 million for Q3 2022, and its period low was $126,000 during Q4 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Receivables Refunds value was $1.3 million (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Receivables Refunds surged by 2,085.58% in 2022 and then slumped by 86.75% in 2023.
  • Amphastar Pharmaceuticals' Receivables Refunds (Quarterly) stood at $126,000 in 2021, then spiked by 35.71% to $171,000 in 2022, then spiked by 207.60% to $526,000 in 2023, then soared by 232.13% to $1.7 million in 2024, then plummeted by 61.39% to $2.1 million in 2025.
  • Its Receivables Refunds was $2.1 million in Q3 2025, compared to $1.6 million in Q2 2025 and $758,000 in Q1 2025.